A Phase 1b/2 Open-label Multicenter Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to learn about the safety of SD-101 and to find out what effects (both good and bad) it has on Melanoma when given along with pembrolizumab.
Description
The purpose of this study is to learn about the safety of SD-101 and to find out what effects (both good and bad) it has on Melanoma when given along with pembrolizumab (MK-3475).
Details
| Condition | melanoma |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX7932 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.